NBIX vs NRIM · P/E 45, rev $1.77B vs P/E 13, rev $123.7M
Neurocrine Biosciences Inc (NBIX) versus Northrim BanCorp Inc (NRIM) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Northrim BanCorp Inc (NRIM) is a banks - regional company listed on US.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported NRIM revenue for 2026-06-30 was $123.7M. Net income was $29.0M. NRIM currently screens at market cap $522.9M and trailing P/E 12.6.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. NRIM currently screens at market cap $522.9M and trailing P/E 12.6.
Not investment advice. Open the NBIX and NRIM stock pages for the full models.
Not investment advice.